Eton Pharmaceuticals Inc

ETON remains in a sustained Stage 2 uptrend reinforced by a Momentum Breakout, but extreme overbought readings and a large extension above EMAs suggest timing is unfavorable. Deferred entry near the 9/20/50 EMA support zone is preferred.

• ↑Q1 ’26 revenue climbed 73% YoY to $24.3M, with FY26 guidance now >$120M
• ↑Adjusted EBITDA margin reached 24% in Q1 and is projected above 30% for 2026
• ↓Negative net margin of -1.7% and ROE of -5.7% highlight weak profitability